• Avalo Therapeutics flagged new Phase 2 LOTUS trial results for abdakibart in moderate-to-severe hidradenitis suppurativa at EADV 2026.
• Results have not been presented yet; a poster is scheduled for Sept. 30, 2026, followed by a late-breaker oral talk on Oct. 1.
• The presentations are set to highlight efficacy and safety outcomes, including subgroup and lesion-type analyses, without disclosing new numerical detail in the announcement.
• Abdakibart is positioned as a selective anti-IL-1β antibody, supporting the company’s strategy in immune-mediated inflammatory diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230700PRIMZONEFULLFEED9831716) on September 23, 2026, and is solely responsible for the information contained therein.